Associate Professor of Medicine, Brigham and Women's Hospital
Cardiology
Dr. Laura Mauri, MD
|
|
Give Review
Laura Mauri practices Cardiology. He graduated from Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School has a rank of 1 in research and a 12 in primary care He over the years received 2 awards: "Meaningful Use Stage 1 Certification" and "Fellow (FACC)". Doctor Laura Mauri, MD is a published doctor. He published 40 publications, including: 'Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.' Laura Mauri, MD is registered with Medicare and accepts Medicare payments.
Publications
- Renal Denervation: Where to Now?
- Causes of late mortality with dual antiplatelet therapy after Coronary stents.
- Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
- Mortality risk with dual antiplatelet therapy?
- Population trends in rates of Coronary revascularization.
- Dual antiplatelet platelet therapy duration following Coronary stenting.
- Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
- Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without Acute Myocardial Infarction.
- Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy.
- Antiplatelet therapy duration following bare metal or drug-eluting Coronary stents: the dual antiplatelet therapy randomized clinical trial.
- Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting Coronary stent placement.
- Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial: Comparing Hospitals and Patients in the Dual Antiplatelet Therapy Study Versus the Nationa...
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents.
- Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis.
- Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
- Delay in reperfusion with transradial percutaneous Coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable?
- Adherence to Dual Antiplatelet Therapy After Coronary Stenting: A Systematic Review.
- A controlled trial of renal denervation for resistant Hypertension.
- Performance of the resolute zotarolimus-eluting stent in small vessels.
- Causes of short-term readmission after percutaneous Coronary intervention.
- Long-term efficacy and safety of zotarolimus-eluting stent in patients with diabetes mellitus: Pooled 5-year results from the ENDEAVOR III and IV trials.
- Comparison of Transradial Versus Transfemoral Percutaneous Coronary Intervention in Routine Practice: Evidence for the Importance of "Falsification Hypotheses" in Obse...
- Instrumental Variable Analysis to Compare Effectiveness of Stents in the Extremely Elderly.
- Frequency of the Use of Low- Versus High-Dose Aspirin in Dual Antiplatelet Therapy After Percutaneous Coronary Intervention (from the Dual Antiplatelet Therapy Study).
- Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive Disease: A meta-analysis and critical examination of current methodologies.
- 4-year results of a randomized controlled trial of percutaneous repair versus surgery for Mitral regurgitation.
- A prediction model to identify patients at high risk for 30-day readmission after percutaneous Coronary intervention.
- Diabetic Heart disease and interventional cardiology: how can clinical outcomes be improved? Revascularization guided by hemodynamic parameters (fractional flow reserve).
- Nonemergency PCI at hospitals with or without on-site cardiac surgery.
- Angiographic characteristics of Coronary arterial segments progressing to myocardial infarction in patients with and without chronic kidney disease.
- Right ventricular perforation and Pulmonary embolism with polymethylmethacrylate cement after percutaneous kyphoplasty.
- Antiplatelet therapy after Coronary stenting.
- Location of Acute coronary artery thromboses in patients with and without chronic kidney disease.
- Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
- Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts.
- Clinical preventability of 30-day readmission after percutaneous Coronary intervention.
- Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.
- Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry's Cat...
- Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report F...
Schools
Harvard Medical School
Brigham and Women39s Hospital
Procedures Preformed
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- Cardioversion, Elective
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Dissection
- View All
Doctors Specialties
- Cardiology
- Interventional Cardiology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Fallon Community Health Plan
- First Health (Coventry Health Care) PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Meaningful Use Stage 1 Certification
- Fellow (FACC)
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1619934924 | |
| NPPES Provider LastName | MAURI | |
| NPPES Provider FirstName | LAURA | |
| NPPES Provider ZIPCode | 021201613 | |
| NPPES Provider State | MA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 21.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1619934924 |
| Last Name Of The Provider | MAURI |
| First Name Of The Provider | LAURA |
| View All |
Similar Doctors
|
|
Dr. Peter J. Zimetbaum, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Bryan P. Yan, MB BS
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ronen Y. Durst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexis Matteau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer Lewey, MD |
|
|
Dr. Maria A. Rupnick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathryn A. Britton, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lauren E. Frost, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark L. Villalon, MD
This Doctor is OpenDoctor Recommended.
|